The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,160,694 in first-year total cost, median $580,347.
Most frequent study sections
- Special Emphasis Panel[ZAI1 MSA-A (J2)]2
Most frequent institutions
- JOHNS HOPKINS UNIVERSITY1
- UNIVERSITY OF WASHINGTON1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Long Acting Injectable Depots for TB Therapy1R61AI161820-01 | STAYTON, PATRICK S. | UNIVERSITY OF WASHINGTON, WA | $686,389 | ZAI1 |
| 2021 | Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosis1R61AI161809-01 | NUERMBERGER, ERIC L | JOHNS HOPKINS UNIVERSITY, MD | $474,305 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.